medecolМедицина и экологияMedicine and ecology2305-60452305-6053Карагандинский медицинский университетmedecol-214Research ArticleКЛИНИЧЕСКАЯ МЕДИЦИНАCLINICAL MEDICINEУРОВЕНЬ 1,5 АНГИДРО-Ә-СОРБИТОЛА У ПАЦИЕНТОВ С РИСКОМ РАЗВИТИЯ ДИАБЕТА 2 ТИПА ПО ШКАЛЕ FINDRISKLEVEL OF 1.5 ANHYDRO-D-SORBTTOL IN PATIENTS WITH RISK OF DIABETES MELLITUS TYPE 2 DEVELOPING ACCORDING TO THE FINDRISK SCALEШерьяздановаД. Н.SheryazdanovaD. N.noemail@neicon.ruЛарюшинаЕ. М.LaryushinaYe. M.noemail@neicon.ruПарахинаВ. Ф.ParakhinaV. F.noemail@neicon.ruШалыгинаА. А.ShatyginaA. A.noemail@neicon.ruБугибаеваА. Б.BugibayevaA. B.noemail@neicon.ruМедицинский университет КарагандыКазахстанKaraganda medical universityKazakhstan202007092021035157Copyright © Шерьязданова Д.Н., Ларюшина Е.М., Парахина В.Ф., Шалыгина А.А., Бугибаева А.Б., 20212021Шерьязданова Д.Н., Ларюшина Е.М., Парахина В.Ф., Шалыгина А.А., Бугибаева А.Б.Sheryazdanova D.N., Laryushina Y.M., Parakhina V.F., Shatygina A.A., Bugibayeva A.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://medecol.qmu.kz/jour/article/view/214

Введение: изучение патогенетических механизмов развития нарушения углеводного обмена у пациентов с риском развития сахарного диабета представляется перспективной темой для исследований. Фундаментальная патогенетическая роль гиперинсулинизма как фактора риска развития сахарного диабета 2 типа установлена во многих проспективных исследованиях. Кроме того, интерес для исследования представляет взаимосвязь параметров регуляции гликемии с феноменом ее вариабельности, которая является основным фактором общей гликемической изменчивости среди используемых на сегодняшний день методов. Предметом изучения в представленной статье являются потенциальные взаимодействия между индексом инсулинорезистентности HOMA-IR и 1,5 ангидро-Д-глицитолом у пациентов с десятилетним риском развития сахарного диабета 2 типа, рассчитанным по шкале FINDRISK. Материалы и методы: 213 пациентов с факторами риска развития сахарного диабета 2 типа. В обеих исследуемых группах были проведены сбор клинических данных, изучение углеводного обмена: глюкоза крови натощак, гликозилированный гемоглобин, инсулин, 1,5 ангидро-Д-глицитола. Статистическая обработка проводилась с использованием критериев Краскела - Уоллиса и ранговой корреляции Спирмена. Результаты и обсуждение: выявлены значимые положительные корреляционные взаимосвязи между 1,5 AG и ИМТ (r=0,213), ОТ (r=0,260), САД (r=0,143), ДАД (r=0,143), ТГ (r=0,147), инсулином (r=0,215) и HOMA-IR (r=0,232), FINDRISK (r=0,161). Заключение: снижение концентрации 1,5-AG ассоциировано с высоким риском развития СД по шкале FINDRISK, что позволяет считать его потенциально полезным маркером оценки риска развития нарушений углеводного обмена.

Introduction: the study of carbohydrate metabolism disorders pathogenesis in patients with diabetes mellitus risk seems to be a promising research direction. The fundamental pathogenetic role of hyperinsulinism as a type 2 diabetes mellitus risk factor has been established in many prospective studies. Nowadays, the interlinks between the parameters of glycemic regulation and the phenomenon of its variability, which is the main factor in the total glycemic variability among the methods used today, is especially promising. The subject of our study in this article is the potential interactions between the HOMA-IR insulin resistance index and 1.5 anhydro-D-glycitol in patients with the ten-year risk of type 2 diabetes mellitus by FINDRISK scale. Materials and methods: 213 patients with risk factors for type 2 diabetes were recruited to the study. We provide collection of clinical data and such carbohydrate metabolism parameters as fasting blood glucose, glycosylated hemoglobin, insulin, 1,5 anhydro-D-glycitol in both study groups. Statistical processing was performed using Kruskal-Wallis one-way analysis of variance, Spearman rank correlation. Resuits and discussion: Significant positive correlation relationships between 1.5 AG and body mass index (r=0.213), waist circumference (r=0.260), systolic blood pressure (r=0.143), diastolic blood pressure (r=0.143), triglycerides (r=0.147), insulin (r=0.215), HOMA-IR (r=0.232), and FINDRISK (r=0.161). Conclusion: decreased 1,5-AG concentration is associated with a high risk of developing diabetes on the FINDRISK scale, which makes it a potentially useful marker for assessing the risk of developing metabolic disorders.

инсулинорезистентностьпреддиабет15 ангидро-Д-глицитолFINDRISKReferences1,5-anhydro-D-glucitol: a novel marker of glucose excursions /M. Dworacka, H. Winiarska, M. Szymanska et al. //Int. J. Clin. Pract. Suppl. - 2002. - V. 129. - P. 40-44.1,5-anhydro-D-glucitol: a novel marker of glucose excursions /M. Dworacka, H. Winiarska, M. Szymanska et al. //Int. J. Clin. Pract. Suppl. - 2002. - V. 129. - P. 40-44.Взаимосвязь уровня биомаркера FABP4 с риском развития сахарного диабета 2 типа /В. Ф. Парахина, Е. М. Ларюшина, Н. В. Васильева //Медицина и экология. - 2018. -№86. - С. 90-97.Взаимосвязь уровня биомаркера FABP4 с риском развития сахарного диабета 2 типа /В. Ф. Парахина, Е. М. Ларюшина, Н. В. Васильева //Медицина и экология. - 2018. -№86. - С. 90-97.A more simplified Finnish diabetes risk score for opportunistic screening of undiagnosed type 2 diabetes in a German population with a family history of the metabolic syndrome /J. Li, A. Bergmann, M. Reimann et al. //Horm Metab Res. -2009. - V. 41, №2. - P. 98-103.A more simplified Finnish diabetes risk score for opportunistic screening of undiagnosed type 2 diabetes in a German population with a family history of the metabolic syndrome /J. Li, A. Bergmann, M. Reimann et al. //Horm Metab Res. -2009. - V. 41, №2. - P. 98-103.A carbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial /J. L. Chiasson, R. G. Josse, R. Gomis et al. // JAMA. - 2003. - V. 290, №4. - P. 486-494.A carbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial /J. L. Chiasson, R. G. Josse, R. Gomis et al. // JAMA. - 2003. - V. 290, №4. - P. 486-494.American Diabetes Association Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018 //Diabetes Care. -2018. - V. 41. - P. 13-27.American Diabetes Association Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018 //Diabetes Care. -2018. - V. 41. - P. 13-27.Association of 1,5-anhydroglucitol and 2-hour postprandial blood glucose in type 2 diabetic patients /C. Stettler, M. Stahl, S. Allemann et al. // Diabetes Care. - 2008. - V. 31. - P. 1534-1535.Association of 1,5-anhydroglucitol and 2-hour postprandial blood glucose in type 2 diabetic patients /C. Stettler, M. Stahl, S. Allemann et al. // Diabetes Care. - 2008. - V. 31. - P. 1534-1535.Cohort Profile: The National FINRISK Study /K. Borodulin, H. Tolonen, P. Jousilahti et al. //International Journal of Epidemiology. -2018. - V. 47, №3. - С. 696-696.Cohort Profile: The National FINRISK Study /K. Borodulin, H. Tolonen, P. Jousilahti et al. //International Journal of Epidemiology. -2018. - V. 47, №3. - С. 696-696.Comparison of 1,5-anhydroglucitol, HbA1C, and fructosamine for detection of diabetes mellitus /T. Yamanouchi, Y. Akanuma, T. Toyota et al. //Diabetes. - 1991. - V. 40. - P. 52-57.Comparison of 1,5-anhydroglucitol, HbA1C, and fructosamine for detection of diabetes mellitus /T. Yamanouchi, Y. Akanuma, T. Toyota et al. //Diabetes. - 1991. - V. 40. - P. 52-57.Da Ros R. Postprandial hyperglycemia and diabetic complications /R. Da Ros, R. Assaloni, A. Ceriello //Recenti Prog Med. - 2005. - V. 96, №9. - P. 436-444.Da Ros R. Postprandial hyperglycemia and diabetic complications /R. Da Ros, R. Assaloni, A. Ceriello //Recenti Prog Med. - 2005. - V. 96, №9. - P. 436-444.Diabetes risk in a Cuban primary care setting in persons with no known glucose abnormalities /A. H. Mohieldein A. A. Naranjo, A. Y. Rodriguez et al. //MEDICC. - 2013. - V. 15. - Р. 16-19.Diabetes risk in a Cuban primary care setting in persons with no known glucose abnormalities /A. H. Mohieldein A. A. Naranjo, A. Y. Rodriguez et al. //MEDICC. - 2013. - V. 15. - Р. 16-19.Efficacy of hemoglobin-Alc, fructosamine, and 1,5-anhydroglucitol in community screening for diabetes mellitus /M. Nagai, K. Sakata, H. Yanagawa et al. //Japanese Journal of Public Health. - 1993. - V. 40, №3. - P. 205-212.Efficacy of hemoglobin-Alc, fructosamine, and 1,5-anhydroglucitol in community screening for diabetes mellitus /M. Nagai, K. Sakata, H. Yanagawa et al. //Japanese Journal of Public Health. - 1993. - V. 40, №3. - P. 205-212.Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired в-cell function, insulin resistance, and worse cardiovascular risk profile: the GENFIEV study /C. Bianchi, R. Miccoli, M. Trombetta et al. //j. Clin. Endocrinol. Metab. -2013. - V. 98, №5. - P. 2100-2105.Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired в-cell function, insulin resistance, and worse cardiovascular risk profile: the GENFIEV study /C. Bianchi, R. Miccoli, M. Trombetta et al. //j. Clin. Endocrinol. Metab. -2013. - V. 98, №5. - P. 2100-2105.ESH/ESC Task Force for the Manage-ment of Arterial Hypertension. Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) //j. Hyper- tens. - 2013. - V. 31, No10. - P. 1925-1938.ESH/ESC Task Force for the Manage-ment of Arterial Hypertension. Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) //j. Hyper- tens. - 2013. - V. 31, No10. - P. 1925-1938.Evaluation of 1,5-anhydroglucitol as a marker for glycemic variability in patients with type 2 diabetes mellitus /M. J. Kim, H. S. Jung, Y. Hwang-Bo et al. //Acta Diabetol. - 2013. - V. 50, №4. - P. 505-510.Evaluation of 1,5-anhydroglucitol as a marker for glycemic variability in patients with type 2 diabetes mellitus /M. J. Kim, H. S. Jung, Y. Hwang-Bo et al. //Acta Diabetol. - 2013. - V. 50, №4. - P. 505-510.Fasting and postchallenge hyperglycemia and risk of cardiovascular disease in Chinese: The Chin-Shan Community Cardiovascular Cohort study /K. L. Chien, H. C. Hsu, T. C. Su et al. //Am. Heart. J. - 2008. - V. 156, №5. - P. 996-1002.Fasting and postchallenge hyperglycemia and risk of cardiovascular disease in Chinese: The Chin-Shan Community Cardiovascular Cohort study /K. L. Chien, H. C. Hsu, T. C. Su et al. //Am. Heart. J. - 2008. - V. 156, №5. - P. 996-1002.Fujita Y. Confirmation of impaired early insulin response to glycemic stimulus in nonobese mild diabetics /Y. Fujita, A. L. Herron Jr., H. S. Seltzer //Diabetes. - 1975. - V. 24, №1. - P. 17-27.Fujita Y. Confirmation of impaired early insulin response to glycemic stimulus in nonobese mild diabetics /Y. Fujita, A. L. Herron Jr., H. S. Seltzer //Diabetes. - 1975. - V. 24, №1. - P. 17-27.Impact of insulin resistance on postprocedural myocardial injury and clinical outcomes in patients who underwent elective coronary interventions with drug-eluting stents /T. Uetani, T. Amano, K. Harada et al. //JACC Cardiovasc Interv. -2012. - V. 5, №11. - P. 1159-1167.Impact of insulin resistance on postprocedural myocardial injury and clinical outcomes in patients who underwent elective coronary interventions with drug-eluting stents /T. Uetani, T. Amano, K. Harada et al. //JACC Cardiovasc Interv. -2012. - V. 5, №11. - P. 1159-1167.Insulin resistance as a predictor for restenosis after coronary stenting /K. Nishio, T. Fukui, F. Tsunoda et al. //Int. J. Cardiol. - 2005. - V. 103, №2. - P. 128-134.Insulin resistance as a predictor for restenosis after coronary stenting /K. Nishio, T. Fukui, F. Tsunoda et al. //Int. J. Cardiol. - 2005. - V. 103, №2. - P. 128-134.Insulin resistance predicts the risk for recurrent coronary events in post-infarction patients /B. Szepietowska, S. McNitt, V. Kutyifa et al. //Cardiol. J. - 2015. - V. 22, №5. - P. 519-526.Insulin resistance predicts the risk for recurrent coronary events in post-infarction patients /B. Szepietowska, S. McNitt, V. Kutyifa et al. //Cardiol. J. - 2015. - V. 22, №5. - P. 519-526.Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study /J. Jeppesen, T. W. Hansen, S. Rasmussen et al. //Am. Heart. J. -2007. - V. 49, №21. - P. 2112-2119.Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study /J. Jeppesen, T. W. Hansen, S. Rasmussen et al. //Am. Heart. J. -2007. - V. 49, №21. - P. 2112-2119.King H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections /H. King, R. E. Aubert, W. H. Herman // Diabetes Care. - 1998. - №21. - P. 1414-1431.King H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections /H. King, R. E. Aubert, W. H. Herman // Diabetes Care. - 1998. - №21. - P. 1414-1431.Kones R. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey //Drug Des. Devel. Ther. - 2011. - V. 5. - P. 325-380.Kones R. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey //Drug Des. Devel. Ther. - 2011. - V. 5. - P. 325-380.Plasma 1,5-anhydro-D- glucitol as new clinical marker of glycemic control in NIDDM patients /T. Yamanouchi, S. Minoda, M. Yabuuchi et al. //Diabetes. - 1989. - V. 38. - P. 723-729.Plasma 1,5-anhydro-D- glucitol as new clinical marker of glycemic control in NIDDM patients /T. Yamanouchi, S. Minoda, M. Yabuuchi et al. //Diabetes. - 1989. - V. 38. - P. 723-729.Relationship between serum 1,5-anhydroglucitol and urinary excretion of N-acetylglucosaminidase and albumin determined at onset of NIDDM with 3-year follow-up /T. Yamanouchi, T. Kawasaki, T. Yoshimura et al. // Diabetes Care. - 1998. - V. 21, №4. - P. 619-624.Relationship between serum 1,5-anhydroglucitol and urinary excretion of N-acetylglucosaminidase and albumin determined at onset of NIDDM with 3-year follow-up /T. Yamanouchi, T. Kawasaki, T. Yoshimura et al. // Diabetes Care. - 1998. - V. 21, №4. - P. 619-624.Risk calculation of developing type 2 diabetes in Libyan adults /A. R. Abduelkarem, S. I. Sharif, A. M. Hammrouni et al. //Pract. Diab. Int. - 2009. - V. 26. - P. 148-151.Risk calculation of developing type 2 diabetes in Libyan adults /A. R. Abduelkarem, S. I. Sharif, A. M. Hammrouni et al. //Pract. Diab. Int. - 2009. - V. 26. - P. 148-151.Risk-stratified screening for diabetes in adults: results of the first investigation in Hungary /G. Winkler, T. Hidvegi, G. Vandorfi et al. // Orv. Hetil. - 2010. - V. 151, №17. - P. 691-696.Risk-stratified screening for diabetes in adults: results of the first investigation in Hungary /G. Winkler, T. Hidvegi, G. Vandorfi et al. // Orv. Hetil. - 2010. - V. 151, №17. - P. 691-696.Serum 1,5-anhydro-D-glucitol and glycemic control in patients with non-insulin-dependent diabetes mellitus /F. Umeda, T. Yamauchi, H. Ishii et al. //J. Exp. Med. - 1991. -V. 163, №2. - P. 93-100.Serum 1,5-anhydro-D-glucitol and glycemic control in patients with non-insulin-dependent diabetes mellitus /F. Umeda, T. Yamauchi, H. Ishii et al. //J. Exp. Med. - 1991. -V. 163, №2. - P. 93-100.

The authors declare that there are no conflicts of interest present.